BML, Inc. (MUN:BMZ)

Market Cap	766.96M +5.4%
Revenue (ttm)	809.87M +5.5%
Net Income	41.07M +24.3%
EPS	1.07 +26.1%
Shares Out	n/a
PE Ratio	18.68
Forward PE	n/a
Dividend	0.67 (3.31%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	n/a
Open	20.40
Previous Close	20.20
Day's Range	20.40 - 20.40
52-Week Range	16.80 - 23.60
Beta	n/a
RSI	27.42
Earnings Date	May 8, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Commercial Physical and Biological Research
• Founded: 1955
• Employees: 4,558
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: BMZ

Financial Performance

In fiscal year 2025, BML, Inc.'s revenue was 143.19 billion, an increase of 3.79% compared to the previous year's 137.96 billion. Earnings were 6.26 billion, an increase of 3.80%.

Financial numbers in JPY